Antibody

Interview: 4-Antibody AG - How do you structure a biotech for divestment?

Interviewee/Contributer: Robert Burns

Organisation: 4-Antibody AG

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Kymab unlocks the power of the mouse

Interviewee/Contributer: Andrew Sandham

Organisation: Kymab Ltd

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Europe to tackle antimicrobial resistance

Interviewee/Contributer: Nigel Gaymond

Full text available to subscribers only. Click here for information on subscribing to MedNous.

The perilous state of antibiotic development

Interviewee/Contributer: Helen Boucher

Organisation: Infectious Diseases Society of America (IDSA)

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Advancing a modular approach to antibody design

Interviewee/Contributer: Kevin FitzGerald

Organisation: F-Star GmbH

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Antibodies show promise against influenza

Interviewee/Contributer: Antonio Lanzavecchia

Organisation: Humabs BioMed SA

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Developing biosimilar monoclonal antibodies will not be easy

Interviewee/Contributer: Gabriele Schaffner-Dallmann

Organisation: Pharmatching GmbH

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Syphogen sees opportunities in antibody mixtures

Interviewee/Contributer: Kirsten Drejer

Organisation: Symphogen A/S

Full text available to subscribers only. Click here for information on subscribing to MedNous.

ArGEN-X builds a new antibody business

Interviewee/Contributer: Tim Van Hauwermeiren

Organisation: ArGenex BV

Full text available to subscribers only. Click here for information on subscribing to MedNous.

EMA guidance on biosimilar monoclonal antibodies

Interviewee/Contributer: Cecil Nick

Organisation: Parexel

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Syndicate content